The contributing factors of resistance or sensitivity to epigenetic drugs in the treatment of AML.
Shohre Karimi KelayeFatemeh NajafiBahareh KazemiZahra ForuzandehFarhad SeifSaeed SolaliMohammad Reza AlivandPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
Drug resistance is the drug-effectiveness reduction in treatment and is a serious problem in oncology and infections. In oncology, drug resistance is a complicated process resulting from enhancing the function of a pump that transports drugs out of tumor cells, or acquiring mutations in drug target. Surprisingly, most drugs are very effective in the early stages, but the response to the drug wears off over time and resistance eventually develops. Drug resistance is caused by genetic and epigenetic changes that affect cancer cells and the tumor environment. The study of inherited changes in the phenotype without changes in the DNA sequence is called epigenetics. Because of reversible changes in epigenetics, they are an attractive target for therapy. Some of these epigenetic drugs are effective in treating cancers like acute myeloid leukemia (AML), which is characterized by the accumulation and proliferation of immature hematopoietic cells in the blood and bone marrow. In this article, we outlined the various contributing factors involved in resistance or sensitivity to epigenetic drugs in the treatment of AML.
Keyphrases
- genome wide
- dna methylation
- acute myeloid leukemia
- copy number
- gene expression
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- palliative care
- drug induced
- randomized controlled trial
- systematic review
- induced apoptosis
- signaling pathway
- oxidative stress
- young adults
- cell death
- endoplasmic reticulum stress
- nucleic acid